Reported Earlier, Zenas Biopharm Announced The Presentation Of Additional Positive Data From The Phase 3 Indigo Trial Evaluating Obexelimab In Immunoglobulin G4-related Disease (Igg4-rd) At The European Alliance Of Associations For Rheumatology (Eular) 2026 Congress In London, England